Evrysdi (risdiplam) 2-year FIREFISH Part 2 data show improvement in motor function in infants with Type 1 spinal muscular atrophy [...]
Head-to-head pivotal clinical trial results showed PONVORYâ„¢ treatment led to nearly a third fewer annual relapses than [...]
Please be advised  of the recent approval by the FDA for intramuscular Plegridy (Peginterferon beta-1a) and an update to other sections [...]
https://youtu.be/vtwauNrp8Jo Ben Thrower, MD, Medical Director, Andrew C. Carlos Multiple Sclerosis Institute, talks about different [...]
7Â 5% of patients with relapsing-remitting multiple sclerosis (RRMS) and suboptimal response to prior treatment had no evidence of disease [...]
First and only FDA-approved subcutaneous treatment option for anti-aquaporin-4 antibody positive NMOSD that can be self-administered by a [...]
HERTFORDSHIRE, England, and PITTSBURGH– August 19, 2020 – Mylan N.V. (NASDAQ: MYL) today announced the launch of the first [...]
Good Day Lemtrada Patient – On July 3, 2020 Sanofi Genzyme was notified that our Lemtrada Home Phlebotomy Partner, Examination [...]
The US FDA has approved inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults who are anti-aquaporin-4 [...]
- Label update is based on data from a large register-based study, as well as other published studies over several decades - Multiple [...]